

Table 1
Reproductive performance of F0 and F1 parental animals.

AS (ppm)		0 (control)	120	600	3000
<i>F0 generation</i>					
No. of rats (male/female)		24/24	24/24	24/24	24/24
Copulation index (%) ^a	Males	91.7	91.7	100	91.7
	Females	95.8	100	100	100
Precoital interval (days) ^b		3.2 ± 1.1	3.2 ± 1.8	2.9 ± 1.3	2.8 ± 1.6
Fertility index (%) ^c	Males	95.5	90.9	100	95.5
	Females	95.7	91.7	100	95.8
Gestation index (%) ^d		100	95.5	95.7	95.7
Gestation length (days) ^b		22.4 ± 0.5	22.5 ± 0.6	22.1 ± 0.4	22.3 ± 0.5
Delivery index (%) ^{b,e}		94.3 ± 5.6	88.6 ± 21.0	90.7 ± 20.8	92.0 ± 20.5
<i>F1 generation</i>					
No. of rats (male/female)		24/24	23/24	24/24	24/24
Copulation index (%) ^a	Males	95.8	91.3	95.8	87.5
	Females	100	95.8	100	95.8
Precoital interval (days) ^b		3.3 ± 3.2	3.0 ± 2.0	2.7 ± 1.5	2.3 ± 1.1
Fertility index (%) ^c	Males	91.3	81.0	91.3	95.2
	Females	91.7	82.6	91.7	91.3
Gestation index (%) ^d		100	94.7	100	100
Gestation length (days) ^b		22.4 ± 0.5	22.3 ± 0.5	22.2 ± 0.4	22.2 ± 0.4
Delivery index (%) ^{b,e}		94.0 ± 9.9	87.5 ± 22.6	91.4 ± 10.7	94.6 ± 6.8

^a Copulation index (%) = (no. of animals with successful copulation/no. of animals paired) × 100.

^b Values are given as the mean ± S.D.

^c Fertility index (%) = (no. of animals that impregnated a female or were pregnant/no. of animals with successful copulation) × 100.

^d Gestation index (%) = (no. of females that delivered live pups/no. of pregnant females) × 100.

^e Delivery index (%) = (no. of pups delivered/no. of implantations) × 100.

decreased significantly in this group, but no significant change was found in the relative weight. In F1 males, the absolute weights of the adrenals at 3000 ppm and the testes at 600 ppm were significantly decreased without significant changes in the relative weight. There were no significant changes in the absolute and relative weights of any organ in F0 and F1 female adults (data not shown).

No dose-related gross lesions were found in F0 or F1 adults. Histopathological examination of the reproductive organs revealed no compound-related alterations. There was no significant difference in the number of primordial follicles in the ovary of F1 females between control and 3000 ppm groups (data not shown).

3.6. Necropsy, organ weight and histopathology of weanlings (F1 and F2)

Absolute and relative organ weights of male and female F1 weanlings are shown in Table 3. The 3000 ppm treated males and females had a significantly lower body weight at scheduled sacrifice than the controls. In this group, absolute and relative liver weights were significantly lower than the controls. Absolute spleen weight was also decreased significantly in both sexes of the 3000 ppm group, accompanied by a significant decrease in the relative weight in males. In addition, significant decreases in the absolute weight were found for the thymus in both sexes and for the kidneys, testes and epididymides in males at 3000 ppm, and for the uterus in females at 600 and 3000 ppm. Relative brain weight was significantly increased in both sexes of the 3000 ppm group.

Table 4 presents absolute and relative organ weights of male and female F2 weanlings. The mean body weight at scheduled sacrifice was significantly lowered in both sexes of the 3000 ppm group. In males, the absolute and relative weights of the thymus and spleen were significantly decreased in the 3000 ppm group. Significant decreases were also found in the absolute weight of the liver and epididymides at 3000 ppm. The relative brain weight was significantly increased at this dose. At 120 ppm, the only significant change was a non-dose-related decrease in the relative thymus weight. In F2 females, there were significant decreases in the absolute and relative weights of the liver, and the absolute weight of the spleen, ovary and uterus, and a significant increase in the relative

brain weight at 3000 ppm. In addition, a significant decrease in the absolute brain weight was observed only in the 600 ppm group.

External and internal gross observations revealed no compound-related alterations either in F1 and F2 weanlings or in pups found dead during the preweaning period. There were no dose-related histopathological changes in the liver and spleen of male and female F1 and F2 weanlings.

4. Discussion

AS administered via the drinking water to male and female rats resulted in decreased water consumption for both sexes in all treatment groups. Since the dosing solution containing AS was pH 3.57–4.20, the acidity would decrease the palatability of drinking water in AS-treated groups. Decreased water consumption was associated with decreased food consumption by F0 and F1 males and females in the 600 and 3000 ppm groups and decreased body weight in F0 male and females in the 3000 ppm group. Since water-deprived animals typically reduce their levels of feed consumption and consequently lower their body weight [46], decreased food consumption and body weight observed in the present study could be considered secondary to the decreased water consumption. In the present study, food consumption and body weight fell notably during the early dosing period in F0 males and females. Food consumption also decreased in F0 and F1 females at the end of the lactation period, when F1 or F2 pups would commence eating and drinking for themselves [37]. Campbell et al. [46] reported that animals have a certain amount of “buffering” capacity in the form of physiological mechanisms acting to reduce fluid loss. This might explain notable changes around the time when rats start drinking AS-containing water.

Continuous drinking of AS-contained water for two generations did not result in changes in copulation, fertility or gestation indices, pre-coital or gestation length, the number of implantations or pups delivered, or the incidence of pups with malformations or variations. In addition, adverse effects were not found in estrous cyclicity or sperm parameters, and the histopathology of reproductive tissues in male and female parental animals. Previous studies have demonstrated that parenterally administered aluminium affected

Table 2
Sex ratio, viability and body weight for F1 and F2 pups.

AS (ppm)	0 (control)	120	600	3000
<i>F1 offspring</i>				
No. of litters	22	21	22	22
No. of pups delivered ^a	13.9 ± 1.7	12.4 ± 4.7	13.1 ± 4.1	13.1 ± 3.4
Sex ratio of pups ^b	0.503	0.462	0.513	0.536
Viability index of pups (%) ^a				
On PND 0 ^c	100.0 ± 0.0	99.3 ± 2.3	99.7 ± 1.6	99.5 ± 2.4
On PND 4 ^d	98.7 ± 2.9	95.2 ± 21.8	98.8 ± 2.6	98.0 ± 5.4
On PND 21 ^e	99.4 ± 2.7	100.0 ± 0.0	100.0 ± 0.0	99.4 ± 2.7
Male pup weight during lactation (g) ^a				
On PND 0	7.05 ± 0.61	7.25 ± 0.99	6.74 ± 0.69	6.96 ± 0.76
On PND 4	11.04 ± 0.85	11.41 ± 1.99	10.86 ± 1.37	11.00 ± 1.06
On PND 7	18.91 ± 1.29	19.36 ± 2.77	18.59 ± 1.71	18.47 ± 1.35
On PND 14	37.70 ± 2.63	37.97 ± 3.08	37.39 ± 2.59	36.34 ± 2.41
On PND 21	62.48 ± 4.50	62.63 ± 6.14	60.77 ± 4.01	57.34 ± 4.86**
Female pup weight during lactation (g) ^a				
On PND 0	6.61 ± 0.55	6.89 ± 0.83	6.35 ± 0.57	6.60 ± 0.64
On PND 4	10.46 ± 0.89	11.06 ± 1.71	10.27 ± 1.33	10.43 ± 0.83
On PND 7	18.03 ± 1.27	18.56 ± 2.31	17.69 ± 1.61	17.61 ± 1.21
On PND 14	36.29 ± 2.71	36.94 ± 3.03	35.67 ± 2.60	35.31 ± 2.24
On PND 21	60.17 ± 4.16	60.87 ± 5.68	57.68 ± 4.33	55.60 ± 4.34**
<i>F2 offspring</i>				
No. of litters	22	18	22	21
No. of pups delivered ^a	13.1 ± 3.6	13.2 ± 3.8	12.6 ± 3.9	14.0 ± 1.9
Sex ratio of pups ^b	0.528	0.502	0.536	0.457
Viability index of pups (%) ^a				
On PND 0 ^c	99.68 ± 1.51	99.49 ± 2.14	98.42 ± 3.57	98.69 ± 3.60
On PND 4 ^d	94.72 ± 14.54	98.07 ± 5.45	99.07 ± 3.15	99.01 ± 2.49
On PND 21 ^e	100.00 ± 0.00	98.61 ± 4.04	100.00 ± 0.00	100.00 ± 0.00
Male pup weight during lactation (g) ^a				
On PND 0	6.97 ± 0.68	6.92 ± 0.81	6.87 ± 0.74	6.89 ± 0.60
On PND 4	10.73 ± 1.62	10.53 ± 1.27	11.27 ± 1.81	10.52 ± 1.15
On PND 7	17.96 ± 2.05	17.51 ± 2.12	18.83 ± 2.39	17.72 ± 1.60
On PND 14	35.79 ± 3.52	36.18 ± 3.63	37.32 ± 4.15	35.44 ± 2.73
On PND 21	59.61 ± 5.45	59.44 ± 5.67	60.12 ± 7.12	56.36 ± 4.47
Female pup weight during lactation (g) ^a				
On PND 0	6.66 ± 0.69	6.38 ± 0.78	6.41 ± 0.65	6.50 ± 0.49
On PND 4	10.22 ± 1.63	9.70 ± 1.23	10.36 ± 1.54	9.98 ± 0.91
On PND 7	17.03 ± 1.99	16.36 ± 2.35	17.40 ± 2.18	16.89 ± 1.23
On PND 14	34.82 ± 3.52	34.17 ± 3.58	34.96 ± 4.24	34.01 ± 2.09
On PND 21	57.33 ± 4.90	56.11 ± 5.54	56.41 ± 6.04	54.16 ± 2.82*

^a Values are given as the mean ± S.D.

^b Sex ratio = total no. of male pups/total no. of pups.

^c Viability index on PND 0 (%) = (no. of live pups on PND 0/no. of pups delivered) × 100.

^d Viability index on PND 4 (%) = (no. of live pups on PND 4/no. of live pups on PND 0) × 100.

^e Viability index on PND 21 (%) = (no. of live pups on PND 21/no. of live pups on PND 4 after cull) × 100.

* Significantly different from the control, $P < 0.05$.

** Significantly different from the control, $P < 0.01$.

male reproductive systems, causing decreases in testicular and epididymal sperm counts, necrosis of spermatocytes/spermatids in the testes, and reduction of fertility, etc., in rats and mice [19,20,47]. Although aluminium has extremely low oral bioavailability (less than 1%) [48,49], male reproductive toxicity was also observed in oral gavage studies [22,23,50]. In the 6-month oral gavage study in rats, changes in the number of spermatozoa and motility, and the substantial proliferation of interstitial cells in the testes were observed at doses as low as 2.5 mg Al/kg/day (as aluminium chloride) [50]. The primary reason why such effects were not detected in the present study might be a difference in the administration method because the toxicokinetic behavior of chemicals given as a bolus dose by gavage must differ significantly from those after continuous administration via drinking water. Another possible factor is aluminium content in the laboratory animal feed, for which substantial brand-to-brand and lot-to-lot variations, ranging from 60 to 8300 ppm, have been reported [51]. Since the dietary intake of aluminium was not considered in these oral gavage studies, toxic effects of aluminium could be overestimated. As for continuous exposure studies, taking into account the aluminium content in the basal diet, Hicks et al. [52] demonstrated that 28-day contin-

uous dietary exposure to basic sodium aluminium phosphate or aluminium hydroxide did not affect the testicular histopathology up to 302 mg Al/kg/day in Sprague–Dawley rats. In the 26-week feeding study of basic sodium aluminium phosphate in beagle dogs, germinal epithelial cell degeneration and atrophy in the seminiferous tubules were observed at 75 mg Al/kg bw/day [21], but such effects on male reproductive organs were not detected up to 88 mg Al/kg/day in the similar subchronic dietary study for acidic sodium aluminium phosphate in beagle dogs [53]. These dietary studies used water-insoluble or sparingly soluble forms of aluminium [8,51]. Since it is widely assumed that insoluble aluminium compounds are less bioavailable than soluble compounds, such as AS, aluminium chloride and aluminium lactate [8], there is a possibility that the male reproductive toxicity of aluminium was underestimated in these previous dietary exposure studies. The present two-generation study provided useful information that the male reproductive system is not affected even after continuous exposure to a water-soluble aluminium compound, at least up to around 50 mg Al/kg bw/day.

In the present study, some developmental effects were observed. Male and female F1 pups and female F2 pups in the

Table 3
Absolute and relative organ weight of F1 male and female weanlings.

AS (ppm)		0 (control)	120	600	3000
<i>Males</i>					
No. of animals		22	20	22	22
Body weight	(g)	90.8 ± 6.9	93.4 ± 10.5	89.7 ± 6.1	79.4 ± 7.5**
Brain	(g)	1.69 ± 0.06	1.73 ± 0.08	1.72 ± 0.07	1.68 ± 0.05
	(g/100 g bw)	1.88 ± 0.13	1.87 ± 0.19	1.92 ± 0.09	2.14 ± 0.17**
Thymus	(mg)	375 ± 55	384 ± 86	357 ± 58	305 ± 51**
	(mg/100 g bw)	414 ± 56	409 ± 64	398 ± 59	383 ± 36
Liver	(g)	4.33 ± 0.43	4.40 ± 0.60	4.22 ± 0.45	3.49 ± 0.53**
	(g/100 g bw)	4.77 ± 0.30	4.71 ± 0.33	4.70 ± 0.27	4.37 ± 0.30**
Kidney ^a	(g)	1.06 ± 0.09	1.09 ± 0.14	1.03 ± 0.11	0.95 ± 0.13**
	(g/100 g bw)	1.17 ± 0.06	1.16 ± 0.07	1.15 ± 0.08	1.20 ± 0.07
Spleen	(mg)	394 ± 49	410 ± 68	388 ± 74	301 ± 43**
	(mg/100 g bw)	436 ± 63	437 ± 40	432 ± 73	379 ± 37**
Testis ^a	(mg)	596 ± 65	583 ± 67	569 ± 65	539 ± 51*
	(mg/100 g bw)	657 ± 64	626 ± 49	635 ± 64	682 ± 58
Epididymis ^a	(mg)	81.8 ± 8.6	76.8 ± 10.9	76.5 ± 8.4	72.0 ± 9.9**
	(mg/100 g bw)	90.4 ± 10.3	82.0 ± 6.1	85.4 ± 8.4	91.5 ± 14.6
<i>Females</i>					
No. of animals		22	20	22	21
Body weight	(g)	84.3 ± 6.3	85.9 ± 9.2	80.5 ± 7.0	75.8 ± 6.4**
Brain	(g)	1.64 ± 0.06	1.66 ± 0.06	1.63 ± 0.05	1.63 ± 0.07
	(g/100 g bw)	1.96 ± 0.12	1.95 ± 0.18	2.04 ± 0.17	2.16 ± 0.14**
Thymus	(mg)	383 ± 66	373 ± 74	345 ± 46	313 ± 33**
	(mg/100 g bw)	453 ± 63	433 ± 64	429 ± 57	415 ± 41
Liver	(g)	3.83 ± 0.47	3.92 ± 0.48	3.61 ± 0.35	3.24 ± 0.34**
	(g/100 g bw)	4.53 ± 0.30	4.57 ± 0.31	4.48 ± 0.30	4.27 ± 0.25*
Kidney ^a	(g)	0.99 ± 0.11	0.99 ± 0.09	0.93 ± 0.10	0.93 ± 0.10
	(g/100 g bw)	1.17 ± 0.08	1.15 ± 0.07	1.15 ± 0.09	1.23 ± 0.09
Spleen	(mg)	337 ± 62	356 ± 55	341 ± 64	292 ± 43*
	(mg/100 g bw)	400 ± 67	415 ± 44	422 ± 53	386 ± 47
Ovary ^a	(mg)	25.3 ± 4.8	25.3 ± 3.8	22.5 ± 4.6	24.7 ± 3.2
	(mg/100 g bw)	30.1 ± 5.1	29.7 ± 5.0	27.9 ± 5.0	32.5 ± 4.2
Uterus	(mg)	70.6 ± 16.6	74.2 ± 32.0	59.2 ± 11.9*	55.4 ± 13.4**
	(mg/100 g bw)	83.8 ± 19.2	85.5 ± 32.4	73.3 ± 11.9	73.3 ± 18.0

Values are given as the mean ± S.D.

^a Values represent the total weights of the organs on both sides.

* Significantly different from the control, $P < 0.05$.

** Significantly different from the control, $P < 0.01$.

3000 ppm group had a lower body weight on PND 21 while no difference was found in the birth weight. Such inhibition of the preweaning body weight gain may be simply attributable to the decreased palatability of the drinking water, which would decrease the water intake of pups themselves or might decrease the amount of maternal breast milk; however, similar developmental effects of aluminium were reported in the previous three dietary exposure studies, in which aluminium lactate was mixed in the diet and fed to mice from day 0 of gestation throughout the lactation period [28,30,32], and the lowest effect level was 500 ppm, which was estimated to be equal to 94–273 mg Al/kg bw/day based on the body weight and food consumption during the lactation period [28]. In these dietary exposure studies, food consumption was decreased, but Golub et al. [28] indicated that the mean body weight of pups on PNDs 15 and 20 in the 1000 ppm group was lower than that of the pair-fed control. In contrast, the effects on body weight of preweaning mice were not found in the other two dietary exposure studies [29,31], which were conducted using a similar study design by the same research group. Donald et al. [29] discussed differences in the constituents of the diet as a possible cause of the inconsistent results, but this speculation appears to be contradicted by a subsequent study [30]. Although it is still unclear why different results were obtained in these dietary exposure studies, these results suggest that the fall in body weight around weaning in the present study might not be explained only by decreased water intake. Aluminium ingested by pups themselves and/or taken via maternal milk may affect preweaning growth, or impairment of maternal nursing behavior or the lactation status could be considered possible factors.

In F1 and F2 weanlings, various organ weight changes were found in the 3000 ppm group. Among them, an increase in the relative brain weight is considered to be a secondary change that occurs with the fall in body weight because the absolute weight did not change. Similarly, decreased absolute weights of the kidneys, testes, epididymides, uterus, etc., without changes in the relative weight, were thought to be associated with decreased body weight. On the other hand, the effects on the liver and spleen, the absolute and relative weights of which were decreased in both generations, could not be explained only by the fall of body weight. Since similar effects were observed in the above-mentioned dietary exposure study of aluminium lactate [28], the effects on the liver and spleen weight might be a direct effect of aluminium ingested by pups themselves and/or taken via maternal milk; however, in the present study, no histopathological changes were detected in the liver and spleen. Furthermore, the changes in the liver or spleen weight were not detected in adults, except for F0 males in the 3000 ppm group; therefore, organ weight changes observed in F1 and F2 weanlings in the 3000 ppm group were not deemed to be adverse effects. Organ weight changes in the 120 and 600 ppm groups were not considered to have toxicological significance because these changes were not dose-dependent or were inconsistent across generations.

As for effects on the developmental landmarks, vaginal opening was slightly delayed in F1 females in the 3000 ppm group while no compound-related changes were found in the other developmental landmarks, including male preputial separation. Vaginal opening generally occurs around the time of first ovulation in response to an increase in serum estradiol levels as females enter puberty [54], and therefore, it is widely used as a marker of female puberty.

Table 4
Absolute and relative organ weight of F2 male and female weanlings.

AS (ppm)		0 (control)	120	600	3000
<i>Males</i>					
No. of animals		21	18	22	21
Body weight	(g)	87.7 ± 5.8	89.0 ± 8.7	87.0 ± 9.6	79.2 ± 6.8**
Brain	(g)	1.66 ± 0.05	1.69 ± 0.06	1.70 ± 0.06	1.67 ± 0.06
	(g/100 g bw)	1.90 ± 0.13	1.91 ± 0.17	1.97 ± 0.16	2.13 ± 0.17**
Thymus	(mg)	382 ± 50	348 ± 49	357 ± 66	305 ± 36**
	(mg/100 g bw)	439 ± 70	392 ± 52*	411 ± 57	386 ± 40**
Liver	(g)	3.93 ± 0.37	4.04 ± 0.64	3.91 ± 0.39	3.45 ± 0.41**
	(g/100 g bw)	4.49 ± 0.34	4.52 ± 0.44	4.50 ± 0.24	4.36 ± 0.23
Kidney ^a	(g)	1.02 ± 0.09	1.01 ± 0.13	0.99 ± 0.13	0.94 ± 0.10
	(g/100 g bw)	1.16 ± 0.08	1.14 ± 0.06	1.14 ± 0.07	1.19 ± 0.06
Spleen	(mg)	368 ± 54	381 ± 62	361 ± 49	296 ± 48**
	(mg/100 g bw)	421 ± 64	427 ± 50	416 ± 48	372 ± 42**
Testis ^a	(mg)	559 ± 67	549 ± 98	543 ± 77	534 ± 54
	(mg/100 g bw)	637 ± 60	615 ± 81	624 ± 47	680 ± 92
Epididymis ^a	(mg)	75.3 ± 6.9	78.3 ± 8.8	75.1 ± 10.7	70.5 ± 5.7*
	(mg/100 g bw)	86.1 ± 8.3	88.4 ± 9.0	86.5 ± 9.0	89.4 ± 8.2
<i>Females</i>					
No. of animals		22	18	21	21
Body weight	(g)	80.8 ± 6.0	80.0 ± 7.2	80.8 ± 9.1	73.8 ± 4.4**
Brain	(g)	1.60 ± 0.06	1.61 ± 0.05	1.64 ± 0.05*	1.61 ± 0.04
	(g/100 g bw)	1.99 ± 0.14	2.03 ± 0.16	2.05 ± 0.20	2.19 ± 0.15**
Thymus	(mg)	337 ± 45	364 ± 36	347 ± 49	312 ± 37
	(mg/100 g bw)	419 ± 61	457 ± 50	431 ± 47	424 ± 54
Liver	(g)	3.56 ± 0.35	3.61 ± 0.39	3.61 ± 0.48	3.07 ± 0.26**
	(g/100 g bw)	4.41 ± 0.21	4.51 ± 0.26	4.47 ± 0.26	4.17 ± 0.29**
Kidney ^a	(g)	0.95 ± 0.07	0.93 ± 0.10	0.92 ± 0.10	0.88 ± 0.08
	(g/100 g bw)	1.18 ± 0.08	1.16 ± 0.09	1.14 ± 0.06	1.20 ± 0.07
Spleen	(mg)	320.9 ± 46.7	331.8 ± 59.3	331.3 ± 57.1	269.9 ± 55.2**
	(mg/100 g bw)	398.4 ± 59.0	414.8 ± 64.3	409.0 ± 42.2	365.0 ± 67.4
Ovary ^a	(mg)	23.9 ± 3.7	22.8 ± 3.6	23.2 ± 3.5	20.2 ± 2.3**
	(mg/100 g bw)	29.7 ± 4.9	28.8 ± 5.6	29.0 ± 4.7	27.5 ± 3.5
Uterus	(mg)	60.5 ± 17.0	63.8 ± 18.4	65.0 ± 41.7	49.3 ± 11.6*
	(mg/100 g bw)	74.6 ± 19.2	79.3 ± 19.3	78.7 ± 40.4	67.0 ± 16.2

Values are given as the mean ± S.D.

^a Values represent the total weights of the organs on both sides.

* Significantly different from the control, $P < 0.05$.

** Significantly different from the control, $P < 0.01$.

On the other hand, vaginal opening is closely related to body weight, and growth retardation can delay the day of acquisition [55]. In the present study, body weight at the time of vaginal opening was slightly heavier in F1 females of the highest dose group, compared with the control. However, other hormone-dependent events, including estrous cyclicity and AGD, were not changed in AS-treated groups. It seems unlikely that aluminium have a clear impact on the hormonal event. Further studies are required to draw a definitive conclusion on the effects of aluminium on the sexual maturation.

Aluminium has been reported to affect the developing nervous system [56,57]. In continuous exposure studies using rodents, the neurobehavioral effects were reported as follows: dietary exposure of pregnant rats to aluminium chloride or lactate at more than 96 mg Al/kg bw/day impaired the righting reflex, gasping reflex, negative geotaxis and/or locomotor coordination of preweaning pups [25,26]. Impaired performance of operant conditioning tasks, accompanied by a decrease in locomotor activity, was observed on PND 65 in the offspring of rats receiving a diet containing aluminium lactate at 400 mg Al/kg bw/day during gestation [58], suggesting that the effects continue after maturation. Unfortunately, aluminium concentration in the basal diet was not reported in these feeding studies using rats. Similar neurobehavioral effects were found in the preweaning, juvenile and adult periods of the offspring after dietary exposure of mice to aluminium lactate throughout the gestation and lactation periods [28–32]. These mouse studies took the basal diet content of the aluminium diet into consideration, and the lowest observed effect level was 500 ppm, corresponding to 100 mg Al/kg bw/day at the beginning of preg-

nancy and 210 mg Al/kg/day near the end of lactation [29]. In the present study, no changes were found in the reflex ontogeny of F1 and F2 pups and in spontaneous locomotor activity tested at 4 weeks of age for F1 animals. As for the performance in a water-filled multiple T-maze, a transient decrease in the elapsed time and the number of errors were found in F1 females in the 600 ppm group, but this change was not considered to be treatment-related because of the lack of dose-dependency. These findings indicate that previous findings of developmental neurotoxic effects were possibly related to the toxic effects of aluminium given at higher doses than those given in this study.

In summary, AS administered via drinking water at 120, 600 or 3000 ppm resulted in decreased water consumption. This change was associated with decreased food consumption in the 600 and 3000 ppm groups and decreased body weight in the 3000 ppm group. In the 3000 ppm group, male and female pups had a lower body weight on PND 21. At this dose, vaginal opening was slightly delayed. No definitive effects were found in the other reproductive/developmental parameters, including developmental neurobehavioral toxicity. Although there is a possibility that observed developmental effects are results of decreased water consumption, more definitive conclusions could not be reached since paired-comparison data are not available to assess the effects of decreased water intake in the absence of AS exposure. Based on these considerations, a conservative evaluation of the data led to the conclusion that the no observed adverse effect level of AS in this two-generation study is 600 ppm (41.0 mg/kg bw/day) for parental systemic toxicity and reproductive/developmental toxicity. The total ingested dose of aluminium from food and drinking

water combined in this 600 ppm group was calculated to be 8.06 mg Al/kg bw/day.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Acknowledgement

This study was supported by the Ministry of Health, Labour and Welfare, Japan.

References

- [1] IPCS (International Programme on Chemical Safety). Aluminium. Environmental health criteria, vol. 194. Geneva: World Health Organization; 1997.
- [2] Lantzy RJ, Fred TM. Atmospheric trace metals: global cycles and assessment of man's impact. *Geochim Cosmochim Acta* 1979;43:511–25.
- [3] Hjortsberg U, Orbaek P, Arborelius Jr M, Karlsson JE. Upper airway irritation and small airways hyperreactivity due to exposure to potassium aluminium tetrafluoride flux: an extended case report. *Occup Environ Med* 1994;51:706–9.
- [4] Jederlinic PJ, Abraham JL, Chung A, Himmelstein JS, Epler GR, Gaensler EA. Pulmonary fibrosis in aluminum oxide workers. Investigation of nine workers, with pathologic examination and microanalysis in three of them. *Am Rev Respir Dis* 1990;142:1179–84.
- [5] Sjogren B, Lidums V, Hakansson M, Hedstrom L. Exposure and urinary excretion of aluminum during welding. *Scand J Work Environ Health* 1985;11:39–43.
- [6] Shore D, Wyatt RJ. Aluminum and Alzheimer's disease. *J Nerv Ment Dis* 1983;171:553–8.
- [7] Lione A. The prophylactic reduction of aluminium intake. *Food Chem Toxicol* 1983;21:103–9.
- [8] IPCS (International Programme on Chemical Safety). Aluminium from all sources, including food additives (addendum). In: Safety evaluation of certain food additives and contaminants, prepared by the sixty-seventh meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), WHO food additives series 58. Geneva: Organization WH; 2007. p. 119–208.
- [9] WHO (World Health Organization). 12.5 Aluminium. Guidelines for drinking-water quality: incorporating the first and second addenda, vol. 1 recommendations, 3rd ed. Geneva: World Health Organization; 2008. p. 301–3.
- [10] Goyer RA, Clarkson JW. Toxic effects of metals. In: Klaassen CD, editor. *Casarett and Doull's toxicology: the basic science of poisons*. 6th ed. New York: McGraw-Hill; 2001. p. 811–67.
- [11] Kerr DNS, Ward MK, Ellis HA, Simpson W, Parkinson IS. Aluminium intoxication in renal disease. In: Chadwick DJ, Whelan J, editors. *Aluminium in biology and medicine* (Ciba Foundation Symposium). Chichester: Wiley; 1992. p. 123–41.
- [12] Rondeau V. A review of epidemiologic studies on aluminum and silica in relation to Alzheimer's disease and associated disorders. *Rev Environ Health* 2002;17:107–21.
- [13] Jansson ET. Aluminum exposure and Alzheimer's disease. *J Alzheimers Dis* 2001;3:541–9.
- [14] Flaten TP. Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water. *Brain Res Bull* 2001;55:187–96.
- [15] Golub MS, Donald JM, Gershwin ME, Keen CL. Effects of aluminum ingestion on spontaneous motor activity of mice. *Neurotoxicol Teratol* 1989;11:231–5.
- [16] Petit TL, Biederman GB, McMullen PA. Neurofibrillary degeneration, dendritic dying back, and learning-memory deficits after aluminum administration: implications for brain aging. *Exp Neurol* 1980;67:152–62.
- [17] Lipman JJ, Colowick SP, Lawrence PL, Abumrad NN. Aluminum induced encephalopathy in the rat. *Life Sci* 1988;42:863–75.
- [18] Strong MJ, Garruto RM. Chronic aluminum-induced motor neuron degeneration: clinical, neuropathological and molecular biological aspects. *Can J Neurol Sci* 1991;18:428–31.
- [19] Lobet JM, Colomina MT, Sirvent JJ, Domingo JL, Corbella J. Reproductive toxicology of aluminum in male mice. *Fundam Appl Toxicol* 1995;25:45–51.
- [20] Guo CH, Lu YF, Hsu GSH. The influence of aluminium exposure on male reproduction and offspring in mice. *Environ Toxicol Pharmacol* 2005;20:135–41.
- [21] Petersen JC, Hackett DS, Zwicker GM, Sprague GL. Twenty-six week toxicity study with KASAL (basic sodium aluminium phosphate) in beagle dogs. *Environ Geochem Health* 1990;12:121–3.
- [22] Yousef MI, El-Morsy AM, Hassan MS. Aluminium-induced deterioration in reproductive performance and seminal plasma biochemistry of male rabbits: protective role of ascorbic acid. *Toxicology* 2005;215:97–107.
- [23] Roy AK, Talukder G, Sharma A. Similar effects in vivo of two aluminum salts on the liver, kidney, bone, and brain of *Rattus norvegicus*. *Bull Environ Contam Toxicol* 1991;47:288–95.
- [24] Paternain JL, Domingo JL, Llobet JM, Corbella J. Embryotoxic and teratogenic effects of aluminum nitrate in rats upon oral administration. *Teratology* 1988;38:253–7.
- [25] Bernuzzi V, Desor D, Lehr PR. Effects of prenatal aluminum exposure on neuromotor maturation in the rat. *Neurobehav Toxicol Teratol* 1986;8:115–9.
- [26] Bernuzzi V, Desor D, Lehr PR. Developmental alternations in offspring of female rats orally intoxicated by aluminum chloride or lactate during gestation. *Teratology* 1989;40:21–7.
- [27] Domingo JL, Paternain JL, Llobet JM, Corbella J. Effects of oral aluminum administration on perinatal and postnatal development in rats. *Res Commun Chem Pathol Pharmacol* 1987;57:129–32.
- [28] Golub MS, Gershwin ME, Donald JM, Negri S, Keen CL. Maternal and developmental toxicity of chronic aluminum exposure in mice. *Fundam Appl Toxicol* 1987;8:346–57.
- [29] Donald JM, Golub MS, Gershwin ME, Keen CL. Neurobehavioral effects in offspring of mice given excess aluminum in diet during gestation and lactation. *Neurotoxicol Teratol* 1989;11:345–51.
- [30] Golub MS, Keen CL, Gershwin ME. Neurodevelopmental effect of aluminum in mice: fostering studies. *Neurotoxicol Teratol* 1992;14:177–82.
- [31] Golub MS, Han B, Keen CL, Gershwin ME, Tarara RP. Behavioral performance of Swiss Webster mice exposed to excess dietary aluminum during development or during development and as adults. *Toxicol Appl Pharmacol* 1995;133:64–72.
- [32] Golub MS, Germann SL. Long-term consequences of developmental exposure to aluminum in a suboptimal diet for growth and behavior of Swiss Webster mice. *Neurotoxicol Teratol* 2001;23:365–72.
- [33] Stauber JL, Florence TM, Davies CM, Adams MS, Buchanan SJ. Bioavailability of Al in alum-treated drinking water. *J Am Water Works Assoc* 1999;91:84–93.
- [34] Schonholzer KW, Sutton RA, Walker VR, Sossi V, Schulzer M, Orvig C, et al. Intestinal absorption of trace amounts of aluminium in rats studied with 26 aluminium and accelerator mass spectrometry. *Clin Sci (Lond)* 1997;92:379–83.
- [35] Taimei Chemicals Co., Ltd. Aluminium sulfate, product introduction. Available at: <http://www.taimei-chem.co.jp/product/01.html> [accessed 16.04.10].
- [36] Donaldson L. The manufacture of aluminium sulfate. New Zealand Institute of Chemistry Website. Available at: <http://nzic.org.nz/ChemProcesses/production/1F.pdf> [accessed 16.04.10].
- [37] OECD (Organisation for Economic Co-operation and Development). Two-generation reproduction toxicity study (Test No. 416, Adopted on January 22, 2001). OECD guidelines for testing of chemicals; 2001.
- [38] MHW (Ministry of Health and Welfare, Japan). The guidelines for designation of food additives, and for revision of standards for use of food additives, Notification by director of Environmental Health Bureau, MHW (Eikahatsu No. 29), dated March 22, 1996.
- [39] ME, METI, MHLW (Ministry of the Environment, Ministry of Economy, Trade and Industry, Ministry of Health, Labour and Welfare, Japan). Standard concerning testing laboratories implementing tests for new chemical substances etc., Joint notification by director generals of Environmental Policy Bureau, ME (Kanpokiatsu No. 031121004) and Manufacturing Industries Bureau, METI (Seikyokuhatsu No. 3), dated November 17, 2003 and by director general of Pharmaceutical and Food Safety Bureau, MHLW (Yakusyokuhatsu No. 1121003), dated November 21, 2003.
- [40] ME, METI, MHLW (Ministry of the Environment, Ministry of Economy, Trade and Industry, Ministry of Health, Labour and Welfare, Japan). Partial amendment to "Standard concerning testing laboratories implementing tests for new chemical substances etc.", Joint notification by director generals of Environmental Policy Bureau, ME (Kanpokiatsu No. 080704001) and Manufacturing Industries Bureau, METI (Seikyokuhatsu No. 2), dated June 30, 2008 and by director general of Pharmaceutical and Food Safety Bureau, MHLW (Yakusyokuhatsu No. 0704001), dated July 4, 2008.
- [41] Japanese animal welfare law "Act on Welfare and Management of Animals". Act No. 105 of October 1, 1973, as amended up to Act No. 68 of June 22, 2005.
- [42] Act on Welfare and Management of Animals, Act No. 105 of October 1, 1973, as amended up to Act No. 68 of June 22, 2005.
- [43] ME (Ministry of the Environment, Japan). Standards Relating to the Care, Management of Laboratory Animals and Relief of Pain. Announcement No. 88 of April 28, 2006.
- [44] MHLW (Ministry of Health, Labour and Welfare, Japan). Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in the Testing Facility under the Jurisdiction of the Ministry of Health, Labour and Welfare. Notification by director of Health Sciences Division, Minister's Secretariat, MHLW (Kahatsu No. 0601005), dated June 1, 2006.
- [45] Biel W. Early age differences in maze performance in albino rats. *J Genet Psychol* 1940;56:439–45.
- [46] Campbell MA, Golub MS, Iyer P, Kaufman FL, Li LH, Moran Messen F, et al. Reduced water intake: implications for rodent developmental and reproductive toxicity studies. *Birth Defects Res B Dev Reprod Toxicol* 2009;86:157–75.
- [47] Kamboj VP, Kar AB. Antitesticular effect of metallic and rare earth salts. *J Reprod Fertil* 1964;7:21–8.
- [48] Jouhannau P, Raisbeck GM, Yiou F, Lacour B, Banide H, Drueke TB. Gastrointestinal absorption, tissue retention, and urinary excretion of dietary aluminum in rats determined by using 26Al. *Clin Chem* 1997;43:1023–8.
- [49] Zafar TA, Weaver CM, Martin BR, Flarend R, Elmore D. Aluminum (26Al) metabolism in rats. *Proc Soc Exp Biol Med* 1997;216:81–5.
- [50] Krasovskii GN, Vasukovich LY, Chariev OG. Experimental study of biological effects of leads and aluminum following oral administration. *Environ Health Perspect* 1979;30:47–51.
- [51] ATSDR (Agency for Toxic Substance and Disease Registry). Toxicological profile for aluminum. Atlanta, Georgia: ATSDR, U.S. Department of Health and Human Services; 2008.
- [52] Hicks JS, Hackett DS, Sprague GL. Toxicity and aluminium concentration in bone following dietary administration of two sodium aluminium phosphate formulations in rats. *Food Chem Toxicol* 1987;25:533–8.

- [53] Katz AC, Frank DW, Sauerhoff MW, Zwicker GM, Freudenthal RI. A 6-month dietary toxicity study of acidic sodium aluminium phosphate in beagle dogs. *Food Chem Toxicol* 1984;22:7–9.
- [54] Holson JF, Nemeč MD, Stump DG, Kaufman LF, Lindström P, Varsho BJ. Significance, reliability, and interpretation of developmental and reproductive toxicity study findings. In: Hood RD, editor. *Developmental and reproductive toxicology—a practical approach*. 2nd ed. Florida: CRC Press, Taylor & Francis Group; 2006. p. 329–424.
- [55] Kennedy GC, Mitra J. Body weight and food intake as initiating factors for puberty in the rat. *J Physiol* 1963;166:408–18.
- [56] Alleva E, Rankin J, Santucci D. Neurobehavioral alteration in rodents following developmental exposure to aluminum. *Toxicol Ind Health* 1998;14:209–21.
- [57] Golub MS, Domingo JL. What we know and what we need to know about developmental aluminum toxicity. *J Toxicol Environ Health* 1996;48:585–97.
- [58] Muller G, Bernuzzi V, Desor D, Hutin MF, Burnel D, Lehr PR. Developmental alterations in offspring of female rats orally intoxicated by aluminum lactate at different gestation periods. *Teratology* 1990;42:253–61.

Original Article

Repeated dose and reproductive/developmental toxicity of perfluorooctadecanoic acid in rats

Mutsuko Hirata-Koizumi¹, Sakiko Fujii², Masatoshi Furukawa², Atsushi Ono¹
and Akihiko Hirose¹

¹Division of Risk Assessment, Biological Safety Research Center, National Institute of Health Sciences,
1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan

²Safety Research Institute for Chemical Compounds Co., Ltd., 363-24 Sin-ei, Kiyota-ku, Sapporo,
Hokkaido 004-0839, Japan

(Received August 19, 2011; Accepted November 3, 2011)

ABSTRACT — Male and female rats were given perfluorooctadecanoic acid (PFOdA) by gavage at 40, 200 or 1,000 mg/kg/day, and each female was mated with a male in the same dose group after 14-day administration. Males were dosed for 42 days and females were dosed throughout the gestation period until day 5 of lactation. One female given 1,000 mg/kg/day was euthanized on day 18 of gestation due to a moribund condition; however, no other treatment-related clinical signs of toxicity were observed. Body weights fell at 1,000 mg/kg/day from day 28 through the administration period in males and throughout gestation and lactation in females. Red blood cell count, hemoglobin level and hematocrit were decreased at 200 and 1,000 mg/kg/day in males and activated partial thromboplastin time was prolonged at 1,000 mg/kg/day in females. Histopathological examination revealed hepatic changes, such as centrilobular hypertrophy and necrosis, in males given 200 and 1,000 mg/kg/day and in females given 1,000 mg/kg/day. Pancreatic zymogen granule was decreased in both sexes at 1,000 mg/kg/day. As for reproductive and developmental toxicity, there were decreases in the number of corpora lutea, implantation, total number of pups born and the number of live pups on postnatal days 0 and 4 at 1,000 mg/kg/day. At this dose, birth weights of pups were decreased and postnatal body weight gain was inhibited. Based on these findings, the NOAEL of PFOdA was considered to be 40 mg/kg/day for repeated dose toxicity and 200 mg/kg/day for reproductive/developmental toxicity.

Key words: Perfluorooctadecanoic acid, Repeated dose toxicity,
Reproductive and developmental toxicity, Screening test, Rat

INTRODUCTION

Perfluoroalkyl acids (PFAAs) consist of a carbon chain surrounded by fluorine atoms and a charged functional moiety (primarily carboxylate, sulfonate or phosphonate) at the end of the carbon chain. Since PFAAs have extremely low surface tension and show a unique hydrophobic and oleophobic nature (Lau *et al.*, 2007), they have been widely used as a surface protectant for paper and packaging products, carpets, leather products and textiles (Hekster *et al.*, 2003; Schultz *et al.*, 2003). They have been also used in industrial surfactants, additives and coatings and in firefighting foam. PFAAs are stable in air at high temperatures, nonflammable, not readily degraded by strong acids, alkalis or oxidizing agents

and not subject to photolysis (Lau *et al.*, 2007). Such stability of PFAAs must be favorable for their use, but as they are also considered to be stable in the environment (non-biodegradable and persistent) (OECD, 2002, 2007; Schultz *et al.*, 2003), there is growing concern regarding the impact on the environment and on human health via the environment.

The most well-known PFAAs are the 8-carbon chemicals: perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA), which are most effective surfactants among PFAAs (Lau *et al.*, 2007). Although the global production volume of PFOS was as high as 3,500 metric tons in 2000 (Lau *et al.*, 2007), the major manufacturer of PFOS, 3M, expressed its intention to discontinue the production of PFOS and related chem-

Correspondence: Mutsuko Hirata-Koizumi (E-mail: mkoizumi@nihs.go.jp)

icals in 2000 and completed its phase-out in 2002 (3M year not specified; US EPA, 2000). PFOS and related chemicals were listed as a persistent organic pollutant under the Stockholm Convention in 2009 (Stockholm Convention, 2010), and are now regulated in the United States, European Union, Canada and Japan (Canada, 2010; US EPA, 2008b; EU, 2006; MHLW, ME and NITE year not specified). The phase-out of PFOS and related chemicals increased the production volume of PFOA to 1,200 metric tons per year by 2004 (Lau *et al.*, 2007); however, in 2006, the United States Environmental Protection Agency and the eight major producers of fluoropolymer/telomer launched the PFOA Stewardship Program, in which manufacturers gave their pledge to reduce global facility emissions and product content of PFOA and related chemicals by 95% by 2010, and to work toward eliminating emissions and product content by 2015 (US EPA, 2008a). Although PFOS and PFOA have been reported to be detected in the environmental media, wildlife and human tissues in many different geographic locations throughout the world (Lau *et al.*, 2007), these industrial and regulatory activities must reduce their concentrations in the future. Of current concern is the anticipated growth of the production of other PFAAs as alternative products and the subsequent increase in their environmental concentrations.

Many toxicological researches on PFOS or PFOA have been carried out, and their hepatotoxicity, including carcinogenic effects, and reproductive/developmental toxicity have been shown in laboratory animals (ATSDR, 2009; US EPA, 2005; Lau *et al.*, 2007; OECD, 2002). Data on the toxic properties of other PFAAs are limited, but they have been studied in recent years (Chengelis *et al.*, 2009; Das *et al.*, 2008; Fang *et al.*, 2008; Lieder *et al.*, 2009a, 2009b; Mertens *et al.*, 2010; Shi *et al.*, 2007; Stump *et al.*, 2008; van Otterdijk 2007a, 2007b; Zhang *et al.*, 2008). Available data indicate that PFAAs with a longer carbon chain are eliminated more slowly from the body (Chang *et al.*, 2008; Ohmori *et al.*, 2003), and their toxic potency increases by lengthening the carbon chain (Kudo *et al.*, 2000, 2006; Permadi *et al.*, 1992). Since the bioaccumulation potential of PFAAs also increases depending on their carbon number (Martin *et al.*, 2003), long-chain PFAAs may cause serious environmental and/or human health concerns in the future. As no data are available for the toxicity of PFAAs with a carbon chain length 13 and above, toxicological researches are needed urgently. In order to obtain initial risk information on the toxicity of such long-chain PFAAs, the Ministry of Health, Labour and Welfare, Japan, conducted repeated dose and reproductive/developmental toxicity screening tests for several

long-chain perfluorocarboxylic acids (carbon chain length C12 to C18) under the Japanese existing chemical safety programme in 2009-2011. The present article reports the result of the study of perfluorooctadecanoic acid [PFODa (C18); CAS No. 16517-11-6] concluded recently.

MATERIALS AND METHODS

This study was conducted in accordance with OECD guideline 422 "Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test" (OECD, 1996) at the Safety Research Institute for Chemical Compounds Co., Ltd. (Sapporo, Japan). All procedures involving the use and care of animals complied with the principles for Good Laboratory Practice (ME, METI and MHLW, 2008) and applicable animal welfare regulations ["Act on Welfare and Management of Animals" (Japanese Animal Welfare Law, 2005) and "Standards Relating to the Care, Management of Laboratory Animals and Relief of Pain" (ME 2006)].

Animals and housing conditions

CrI:CD(SD) rats (8 weeks old) were purchased from Atsugi Breeding Center, Charles River Laboratories Japan, Inc. (Kanagawa, Japan). They were acclimated to the laboratory for 13 days, and then rats found to be in good health were divided into each dose group by stratified random sampling based on body weight. For female animals, vaginal smears were prepared daily to examine the estrous cycle for 9 days before assignment to each group, but no abnormalities were found in any animal.

Throughout the study, animals were maintained in an air-conditioned room with controlled temperature ($22 \pm 3^\circ\text{C}$) and humidity ($50 \pm 20\%$). Light was provided on a 12-hr light/dark cycle (light: 8:00-20:00). The animals were housed individually, except during acclimation, mating and nursing periods, in metal bracket-type cages with wire-mesh floors. From day 17 of gestation to day 4 after delivery, individual dams and litters were reared using wood chips as bedding (White Flake; Charles River Laboratories Japan, Inc.). All animals were fed *ad libitum* with a standard rat diet (CRF-1; Oriental Yeast Co., Ltd., Tokyo, Japan), and had free access to tap water (Sapporo, Japan).

Chemicals and dosing

PFODa was purchased from Exflur Research Corporation (Round Rock, TX, USA). The PFODa (Lot No. 3654) used in this study was 98.9% pure, and was kept at room temperature in a dark place. The test article was suspended in a 0.5% aqueous solution of carboxymethylcel-

Repeated dose and reproductive/developmental toxicity of PFOdA

lulose sodium (CMC-Na; Maruishi Pharmaceutical Co., Ltd., Osaka, Japan), and administered to the animals by gastric intubation. Control rats received the vehicle alone. The daily application volume (10 ml/kg body weight) was calculated according to the latest body weight.

Before the start of the study, the stability of PFOdA in a 0.5% CMC-Na aqueous solution at concentrations of 1 and 100 mg/ml was confirmed after 8-hr storage at room temperature following 15-day refrigerated storage; therefore, dosing solutions were prepared at least once per 15 days and kept in a cool (2.0-6.7°C) and dark place under airtight conditions until dosing. The concentrations of PFOdA in the formulations were analyzed at the first and last preparation using high-performance liquid chromatography-tandem mass spectrometry, and were confirmed to be 85.0 to 115% of the target.

Experimental design

Twelve male rats and twelve female rats were daily administered PFOdA at 0 (vehicle control), 40, 200 or 1,000 mg per kilogram of body weight per day (mg/kg/day). The dose levels were determined based on the previous dose-finding study in which male and female rats were given PFOdA by gavage at 0, 30, 100, 300 or 1,000 mg/kg/day for 14 days. In that study, inhibition of body weight gain, grossly enlarged liver with an increase in the organ weight and various changes in blood biochemical parameters were observed in the 1,000 mg/kg/day group. Increased liver weight was also found in males given 300 mg/kg/day, but there were no treatment-related changes in any examined parameter at 30 and 100 mg/kg/day.

After 14-day administration, each female was mated with a male rat in the same dose group, and pregnant females were allowed to deliver spontaneously and nurse their pups. Males were dosed for 42 days, including the mating period, and seven males in the control and 1,000 mg/kg/day groups and all males in the 40 and 200 mg/kg/day groups were necropsied on the day after the last treatment (main group). The remaining 5 males in the control and 1,000 mg/kg/day groups were further maintained for 2 weeks without PFOdA treatment and then necropsied (recovery group). For females, administration of PFOdA was continued throughout the mating and gestation periods until day 5 of lactation (total administration period: 42-56 days), and all twelve females were necropsied on the day after the last treatment (main group). Aside from these animals, 5 females were given 0 or 1,000 mg/kg/day PFOdA for 42 days without mating and were necropsied after the 14-day recovery period (recovery group). The first day of dosing was designated as day 1 of administration and the day after the final dose as day 1 of the

recovery period.

Observation and examinations

Repeated dose toxicity data

Throughout the study, all animals were observed twice daily for general appearance and behavior during the administration period (before and after the administration) and during the recovery period (morning and afternoon). In addition, detailed clinical observations were conducted using a standardized scoring system for all of the animals once a week throughout the administration and recovery periods. Evaluations included observations in the home cage, during handling and outside the home cage in an open field.

Body weight was measured on days 1, 3, 5, 7, 10, 14, 21, 28, 35 and 42 of the dosing period and on days 7 and 14 of the recovery period. For females exhibiting evidence of successful mating (main group), body weight was recorded on days 0, 1, 3, 5, 7, 10, 14, 17 and 20 of gestation and on days 0, 1 and 4 of lactation. Food consumption was measured at a similar interval throughout the study, except during cohabitation.

At the end of the administration and recovery period, five males and five females per dose were subjected to the following functional observations: (i) sensory reactivity to visual, tactile, auditory, pain and proprioceptive stimuli was assessed on an examination table, (ii) forelimb and hindlimb grip strength was measured three times with a CPU gauge (Aikoh Engineering Co., Ltd., Osaka, Japan), and (iii) spontaneous motor activity was recorded for 1 hr at intervals of 10 min using an automated activity monitor system [SUPERMEX and CompAct AMS (Muromachi Kikai Co., Ltd., Tokyo, Japan)].

Urinalysis was performed at the end of the administration and recovery periods for five males per dose selected for functional observations and for five females per dose in the recovery group. Urine was collected for 3 hr in the metabolism cage, and examined for color and dipstick parameters, such as occult blood, pH, protein, glucose, ketone bodies, bilirubin and urobilinogen. A 21-hr urine sample was also collected to measure the volume of the urine and the specific gravity.

For hematology and blood biochemistry, blood samples were collected from the abdominal aorta of five males and females per dose each in the main and recovery groups at necropsy under ether anesthesia after overnight starvation. One portion of the blood was treated with ethylenediaminetetraacetic acid dipotassium (EDTA-2K) and examined for the red blood cell count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin

concentration (MCHC), white blood cell count, platelet count, reticulocyte count and differential count of white blood cells. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were measured using plasma separated from another blood sample treated with 3.8% sodium citrate. Further, serum or plasma prepared from the remaining portions of blood was analyzed for total protein, albumin, protein fraction ratio, glucose, total cholesterol, triglyceride, total bilirubin, urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) γ -glutamyltranspeptidase (γ -GTP), calcium, inorganic phosphorus, sodium, potassium and chloride.

All surviving animals were euthanized by exsanguination under deep ether anesthesia on the day after the final administration (main group) or after completion of the recovery period (recovery group). The external surfaces and cavity of the body and the organs and tissues of the entire body were examined macroscopically. The brain, thymus, heart, liver, spleen, kidney, adrenal gland, testis, epididymis and ovary were isolated and weighed. Further, the spinal cord, pituitary gland, thyroid, esophagus, stomach, pancreas, duodenum, jejunum, ileum, cecum, colon, rectum, trachea, lung (after tracheal infusion fixation), urinary bladder, prostate, seminal vesicle, uterus, eyeball, Harderian gland, mammary gland, femur (including bone marrow), lymph nodes (mesenteric and mandibular), sciatic nerve as well as grossly abnormal tissues were removed. The eyeball and Harderian gland were fixed and preserved with Davidson's fixative solution. The testis and epididymis were fixed with Bouin's solution and preserved in 70% ethanol. The other organs were stored in 10% neutral-buffered formalin. Histopathological evaluations were performed for five males and females in the control and 1,000 mg/kg/day group. All preserved organs were sectioned, stained with hematoxylin-eosin, and examined histopathologically under a light microscope. Since histopathological changes suggestive of fatty changes of the liver and hemosiderin deposit in the liver and spleen were observed, additional specimens of the liver stained with Berlin blue or with oil red O and specimens of the spleen stained with Berlin blue were prepared and examined microscopically to confirm the observed findings. If treatment-related histopathological changes were found, the same tissues from the remaining animals were then examined.

Reproductive/developmental toxicity data

For each female, daily vaginal lavage samples were evaluated for estrous cyclicity from the first day of administration until evidence of copulation was detected in the

main group and until the necropsy day in the recovery group. Females having repeated 4-6 day estrous cycles were judged to have normal estrous cycles.

In the main group, each female was transferred to the home cage of a randomly chosen male from the same exposure group on day 14 of administration, and cohabited on a 1:1 basis until successful copulation occurred or the mating period of 2 weeks had elapsed. The presence of sperm in the vaginal smear and/or a vaginal plug was considered as evidence of successful mating, and the day of successful mating was designated as day 0 of gestation. Females that did not mate successfully during the 2-week mating period were cohabited with another male from the same group who had been proven to copulate. Following confirmation of mating, females were returned to their home cages and allowed to deliver spontaneously and nurse their pups. They were checked at least three times daily on days 21-25 of gestation, and the day on which dams held their pups under the abdomen in the nest by 9:00 was designated as day 0 of lactation or postnatal day (PND) 0. Precoital interval and gestational length were recorded, and the copulation index, fertility index and gestation index were computed for each dose group.

On PND 0, all live and dead pups born were counted, and live pups were sexed and examined grossly. They were observed daily for general appearance and behavior, and the body weight of live pups was recorded on PNDs 0, 1 and 4. On PND 4, the pups were euthanized by inhalation of carbon dioxide and subjected to a gross external and internal observation. For the pups with gross abnormalities, the whole body was stored in 10% neutral-buffered formalin. At necropsy of maternal animals, the numbers of corpora lutea and implantation in the uterus were recorded, and the implantation index, delivery index, live birth index and viability index were calculated for each group.

Statistical analysis

Body weight, food consumption, grip strength, spontaneous motor activity, urine volume, hematological and blood biochemical findings, organ weights, length of estrous cycle, precoital interval, the number of corpora lutea and implantation, implantation index, gestational length, the number of pups born and live pups on PNDs 0 and 4 and delivery index were evaluated by Bartlett's test for homogeneity of variances ($p \leq 0.05$). The live birth index, neonatal sex ratio, viability index and body weight of male and female pups were similarly analyzed using the litter as the experimental unit. When homogeneity was recognized, one-way analysis of variance was applied ($p \leq 0.10$). If a significant difference was found, Dunnett's

Repeated dose and reproductive/developmental toxicity of PFOdA

test was used for pairwise comparisons between control and individual treatment groups ($p \leq 0.01$ or 0.05). Data without homogeneity were subjected to the Kruskal-Wallis test ($p \leq 0.10$), and if significant differences were detected, the Mann-Whitney U test was used to compare PFOdA-treated groups with the control group ($p \leq 0.01$ or 0.05).

For detailed clinical and functional observations, qualitative parameters of urinalysis, specific gravity of urine and histopathological findings with multiple grades, the trend for each group was evaluated by the Kruskal-Wallis test ($p \leq 0.10$). If significant differences were found, the data were compared between the control and each dosage group using Mann-Whitney U test ($p \leq 0.01$ or 0.05). The incidence of females with normal estrous cycles, copulation, fertility and gestation index and histopathological findings with single grade were analyzed using chi-square test or Fisher's exact test ($p \leq 0.01$ or 0.05).




Fig. 1. Body weight changes of male rats dosed orally with PFOdA. **: Significantly different from the control, $p \leq 0.01$.




Fig. 2. Body weight changes of female rats dosed orally with PFOdA. *: Significantly different from the control, $p \leq 0.05$, **: Significantly different from the control, $p \leq 0.01$.

RESULTS

Clinical and functional observations


One female given 1,000 mg/kg/day in the main group was euthanized on day 18 of gestation due to a moribund condition with bleeding from the vagina, hypothermia, decreased locomotor activity and pale skin. Histopathological examination did not identify the cause of the moribund condition. No treatment-related clinical signs of toxicity were observed in other animals. Detailed clinical observation also revealed no abnormalities during the administration and recovery periods.

In the functional observation, a significant decrease in forelimb grip strength was found at 1,000 mg/kg/day at the end of the administration period (day 4 of lactation) in the female main group (860.4 ± 74.8 g, compared with 1065.2 ± 104.7 g in control, $p \leq 0.05$). Such effects were not observed in males and in the female recovery group at the end of either the administration or recovery period (data not shown). No other treatment-related changes were found in functional observations at the end of the administration and recovery period.

Body weight and food consumption

In males, body weight was significantly lower at 1,000 mg/kg/day than in the control from day 28 through the administration and recovery periods (Fig. 1). Body weight of females showed a significantly lower value at 1,000 mg/kg/day from day 14 of administration through the gestation and lactation periods in the main group and from day 14 through the administration and recovery periods in the recovery group (Fig. 2).

Food consumption was significantly decreased on days 35 and 42 of administration in males given 1,000



mg/kg/day (Fig. 3). In females, a significant decrease in food consumption was found on day 5 of gestation and on day 4 of lactation at 200 mg/kg/day and from day 7 through the administration period, except for days 1 and 20 of gestation at 1,000 mg/kg/day in the main group, and from days 14 to 35 of administration at 1,000 mg/kg/day in the recovery group (Fig. 4). There were no significant changes in food consumption during the recovery period in either sex.

Urinalysis

No significant difference was seen in any urinalysis parameters between the control and PFOdA-treated groups either at the end of the administration period or at the end of the recovery period (data not shown).

Hematology

Red blood cell count, hemoglobin level and hemat-





Fig. 3. Food consumption of male rats dosed orally with PFOdA. *: Significantly different from the control, $p \leq 0.05$, **: Significantly different from the control, $p \leq 0.01$.



ocrit were significantly decreased in males given 200 mg/kg/day and above at the end of the administration period (Table 1). These changes remained significant at the end of the recovery period. In males given 1,000 mg/kg/day, the reticulocyte ratio was significantly lower at the end of the administration period, but it was significantly higher than that of the control after the recovery period. At the end of the recovery period, APTT was significantly prolonged at 1,000 mg/kg/day in males.

In the female main group, the differential leukocyte count revealed a significant increase in basophils in the 1,000 mg/kg/day group (Table 1). There was also a significant reduction of PT at 200 and 1,000 mg/kg/day and a significant prolongation of APTT at 1,000 mg/kg/day in females in the main group. In the female recovery group, a significant reduction of PT, a significant prolongation of APTT, significant increases in MCHC, total white blood cell count and differential lymphocyte count, and a significant decrease in MCV were found at 1,000 mg/kg/day.

Blood biochemistry

At the completion of the administration period, total protein was significantly lower at 1,000 mg/kg/day than in the control in males (Table 2). In the protein fraction, the albumin ratio was significantly increased at 200 mg/kg/day and above, and there was also a significant decrease in the α_1 -globulin ratio and increase in the γ -globulin ratio at 1,000 mg/kg/day in males. Further, significantly higher values in ALT, ALP, total bilirubin and BUN were found at 1,000 mg/kg/day in the male main group. Significant increases in the albumin fraction and ALP and significant decreases in total protein and the α_1 -globulin fraction remained after the recovery period in males given 1,000 mg/kg/day. There was also a significant decrease in the




Fig. 4. Food consumption of female rats dosed orally with PFOdA. *: Significantly different from the control, $p \leq 0.05$, **: Significantly different from the control, $p \leq 0.01$.

Table 1. Hematological findings in male and female rats given PFOdA

Dose (mg/kg/day)	Main Group				Recovery Group	
	0 (control)	40	200	1000	0 (control)	1000
MALE						
Number of animals examined	5	5	5	5	5	5
Red blood cells ($10^4/\mu\text{l}$)	941 \pm 26	907 \pm 25	865 \pm 30**	829 \pm 51**	927 \pm 27	804 \pm 28**
Hemoglobin (g/dl)	16.3 \pm 0.6	16.3 \pm 0.5	15.2 \pm 0.5*	14.7 \pm 0.9**	16.1 \pm 0.4	13.9 \pm 0.7**
Hematocrit (%)	46.0 \pm 1.7	46.0 \pm 1.6	42.6 \pm 1.0*	40.6 \pm 2.0**	44.8 \pm 1.3	39.4 \pm 2.2**
MCV (fl)	48.9 \pm 2.0	50.8 \pm 2.0	49.3 \pm 0.7	49.3 \pm 0.7	48.4 \pm 1.5	49.0 \pm 1.7
MCH (pg)	17.3 \pm 0.6	18.0 \pm 0.7	17.6 \pm 0.3	17.7 \pm 0.7	17.4 \pm 0.3	17.2 \pm 0.4
MCHC (g/dl)	35.5 \pm 0.3	35.5 \pm 0.4	35.7 \pm 0.4	36.1 \pm 0.5	36.0 \pm 0.6	35.2 \pm 0.6
Reticulocyte (%)	3.29 \pm 0.39	2.71 \pm 0.51	3.09 \pm 0.66	2.24 \pm 0.46*	3.35 \pm 0.38	4.98 \pm 0.80**
Platelet ($10^4/\mu\text{l}$)	117.3 \pm 20.7	99.3 \pm 17.3	114.1 \pm 14.1	123.8 \pm 8.5	120.8 \pm 20.4	111.7 \pm 6.1
White blood cells ($10^3/\mu\text{l}$)	94.6 \pm 20.4	89.2 \pm 16.0	92.8 \pm 25.5	120.5 \pm 33.6	118.5 \pm 25.3	136.0 \pm 28.9
Neutrophil ($10^3/\mu\text{l}$)	15.8 \pm 5.2	18.9 \pm 8.3	13.6 \pm 6.6	20.2 \pm 11.6	16.3 \pm 4.3	13.9 \pm 2.2
Lymphocyte ($10^3/\mu\text{l}$)	74.0 \pm 15.5	66.1 \pm 9.9	74.9 \pm 18.1	95.3 \pm 32.5	95.1 \pm 24.3	116.6 \pm 27.6
Monocyte ($10^3/\mu\text{l}$)	3.66 \pm 1.84	2.84 \pm 0.83	3.00 \pm 1.23	3.32 \pm 1.85	5.10 \pm 0.99	4.22 \pm 0.90
Eosinophil ($10^3/\mu\text{l}$)	1.14 \pm 0.71	1.42 \pm 0.74	1.22 \pm 0.67	1.64 \pm 1.21	1.98 \pm 1.12	1.24 \pm 0.31
Basophil ($10^3/\mu\text{l}$)	0.02 \pm 0.04	0.02 \pm 0.04	0.00 \pm 0.00	0.06 \pm 0.05	0.04 \pm 0.05	0.02 \pm 0.04
PT (sec)	20.2 \pm 3.3	19.9 \pm 2.2	20.5 \pm 2.6	21.0 \pm 2.7	17.8 \pm 0.8	19.3 \pm 1.8
APTT (sec)	27.7 \pm 3.4	26.8 \pm 2.7	26.0 \pm 2.9	29.2 \pm 1.7	25.6 \pm 2.0	28.8 \pm 1.0*
FEMALE						
Number of animals examined	5	5	5	5	5	5
Red blood cells ($10^4/\mu\text{l}$)	809 \pm 18	815 \pm 30	820 \pm 25	814 \pm 24	846 \pm 20	819 \pm 60
Hemoglobin (g/dl)	15.0 \pm 0.3	15.7 \pm 0.5*	15.5 \pm 0.4	14.8 \pm 0.4	15.4 \pm 0.5	14.4 \pm 1.0
Hematocrit (%)	42.6 \pm 0.8	45.1 \pm 1.4*	44.5 \pm 1.5	42.0 \pm 1.6	43.3 \pm 1.7	40.0 \pm 2.7
MCV (fl)	52.6 \pm 1.7	55.5 \pm 2.8	54.4 \pm 1.5	51.6 \pm 1.5	51.1 \pm 1.4	48.9 \pm 1.5*
MCH (pg)	18.5 \pm 0.6	19.3 \pm 0.7	18.9 \pm 0.4	18.2 \pm 0.4	18.1 \pm 0.4	17.6 \pm 0.6
MCHC (g/dl)	35.1 \pm 0.4	34.9 \pm 1.0	34.8 \pm 0.4	35.4 \pm 0.5	35.5 \pm 0.2	35.9 \pm 0.2*
Reticulocyte (%)	8.63 \pm 1.15	9.35 \pm 3.39	8.24 \pm 2.08	6.23 \pm 0.48	3.23 \pm 0.20	3.06 \pm 1.52
Platelet ($10^4/\mu\text{l}$)	141.5 \pm 34.1	111.0 \pm 13.9	137.6 \pm 12.3	135.5 \pm 12.7	119.7 \pm 11.4	125.4 \pm 28.2
White blood cells ($10^3/\mu\text{l}$)	102.8 \pm 17.6	106.6 \pm 25.1	99.6 \pm 24.9	144.7 \pm 53.6	68.0 \pm 12.2	91.9 \pm 16.1*
Neutrophil ($10^3/\mu\text{l}$)	23.2 \pm 6.6	25.8 \pm 12.1	14.1 \pm 4.0	27.9 \pm 16.3	11.9 \pm 2.9	11.2 \pm 7.1
Lymphocyte ($10^3/\mu\text{l}$)	72.0 \pm 19.2	71.6 \pm 15.2	79.4 \pm 21.8	107.5 \pm 37.6	52.2 \pm 9.0	75.1 \pm 12.3*
Monocyte ($10^3/\mu\text{l}$)	6.42 \pm 1.45	7.26 \pm 1.09	4.70 \pm 1.56	7.10 \pm 1.58	2.78 \pm 1.01	4.38 \pm 3.11
Eosinophil ($10^3/\mu\text{l}$)	1.22 \pm 0.22	1.90 \pm 0.73	1.40 \pm 0.66	2.02 \pm 0.88	1.10 \pm 0.44	1.22 \pm 0.45
Basophil ($10^3/\mu\text{l}$)	0.02 \pm 0.04	0.02 \pm 0.04	0.00 \pm 0.00	0.14 \pm 0.05*	0.00 \pm 0.00	0.06 \pm 0.05
PT (sec)	18.2 \pm 0.3	17.4 \pm 0.8	16.3 \pm 0.4**	16.1 \pm 0.9**	16.9 \pm 0.4	15.1 \pm 1.3*
APTT (sec)	19.6 \pm 1.0	20.8 \pm 1.5	20.1 \pm 0.9	22.2 \pm 2.20*	20.4 \pm 0.9	27.0 \pm 4.4**

Values are given as the mean \pm S.D.*: Significantly different from the control, $p \leq 0.05$ **: Significantly different from the control, $p \leq 0.01$

Repeated dose and reproductive/developmental toxicity of PFOdA

Table 2. Blood biochemical findings in male and female rats given PFOdA

Dose (mg/kg/day)	Main Group				Recovery Group	
	0 (control)	40	200	1000	0 (control)	1000
MALES						
Number of animals examined	5	5	5	5	5	5
Total protein (g/dl)	5.68 ± 0.22	5.34 ± 0.29	5.50 ± 0.19	5.10 ± 0.19**	5.68 ± 0.15	5.40 ± 0.21*
Albumin (g/dl)	2.79 ± 0.07	2.75 ± 0.14	2.90 ± 0.08	2.88 ± 0.07	2.81 ± 0.05	3.14 ± 0.16**
Protein fraction (%)						
Albumin	49.2 ± 0.7	51.6 ± 1.6	52.8 ± 2.2*	56.7 ± 2.3**	49.4 ± 2.2	58.1 ± 1.5**
Globulin α ₁	23.1 ± 2.5	19.8 ± 2.3	19.6 ± 2.2	13.7 ± 1.3**	21.6 ± 2.7	15.7 ± 1.5**
Globulin α ₂	7.24 ± 0.94	7.94 ± 0.98	7.24 ± 0.43	7.24 ± 1.01	7.14 ± 0.46	7.20 ± 0.70
Globulin β	15.8 ± 0.9	16.0 ± 1.5	15.5 ± 1.2	14.5 ± 1.1	17.0 ± 0.6	14.1 ± 0.7**
Globulin γ	4.72 ± 0.58	4.76 ± 0.56	4.84 ± 0.39	7.92 ± 1.85**	4.82 ± 0.59	4.88 ± 0.75
AST (IU/l)	67.4 ± 8.0	73.6 ± 7.3	72.8 ± 6.9	83.4 ± 16.8	67.4 ± 6.9	74.0 ± 6.5
ALT (IU/l)	30.4 ± 3.2	35.4 ± 8.4	35.0 ± 7.1	46.4 ± 9.7*	34.6 ± 3.1	43.0 ± 9.4
ALP (IU/l)	373 ± 46	387 ± 32	475 ± 74	703 ± 90**	325 ± 93	539 ± 112*
γ-GTP (IU/l)	0.70 ± 0.12	0.76 ± 0.17	0.48 ± 0.04**	0.50 ± 0.30	0.56 ± 0.21	0.50 ± 0.19
Total bilirubin (mg/dl)	0.048 ± 0.016	0.042 ± 0.004	0.030 ± 0.007	0.128 ± 0.027**	0.076 ± 0.015	0.070 ± 0.007
Glucose (mg/dl)	153 ± 16	159 ± 26	155 ± 14	139 ± 10	169 ± 11	163 ± 10
Total cholesterol (mg/dl)	48.4 ± 10.7	44.4 ± 15.4	42.2 ± 16.8	55.2 ± 12.2	57.4 ± 9.8	75.8 ± 23.8
Triglyceride (mg/dl)	33.4 ± 23.7	28.2 ± 30.3	26.4 ± 9.8	17.0 ± 5.8	49.6 ± 9.8	16.2 ± 4.3**
BUN (mg/dl)	16.0 ± 1.2	15.7 ± 0.6	15.3 ± 1.2	22.6 ± 1.9**	16.7 ± 1.8	18.7 ± 2.0
FEMALES						
Number of animals examined	5	5	5	5	5	5
Total protein (g/dl)	6.26 ± 0.21	6.02 ± 0.24	6.34 ± 0.35	6.04 ± 0.24	6.92 ± 0.44	5.98 ± 0.79*
Albumin (g/dl)	2.99 ± 0.17	2.97 ± 0.20	3.28 ± 0.29	3.12 ± 0.30	3.87 ± 0.30	3.64 ± 0.38
Protein fraction (%)						
Albumin	47.8 ± 1.6	49.3 ± 1.6	51.6 ± 2.9	51.6 ± 3.9	55.9 ± 1.5	61.1 ± 3.2*
Globulin α ₁	21.2 ± 2.0	18.2 ± 2.5	17.7 ± 1.8*	16.4 ± 1.7**	17.4 ± 1.3	12.8 ± 2.5**
Globulin α ₂	8.12 ± 0.96	8.32 ± 0.86	7.58 ± 0.71	8.32 ± 1.43	5.96 ± 0.30	6.68 ± 0.86
Globulin β	18.5 ± 0.7	18.9 ± 1.5	18.2 ± 2.3	16.6 ± 1.5	14.3 ± 0.6	12.9 ± 0.7**
Globulin γ	4.40 ± 1.24	5.22 ± 0.83	4.84 ± 1.00	6.98 ± 0.93**	6.42 ± 0.90	6.52 ± 1.69
AST (IU/l)	82.6 ± 23.7	74.4 ± 11.1	81.6 ± 16.3	98.8 ± 36.9	120.2 ± 97.0	124.0 ± 134.3
ALT (IU/l)	29.8 ± 5.3	29.0 ± 2.1	31.2 ± 5.8	35.8 ± 5.8	58.2 ± 52.9	72.4 ± 87.2
ALP (IU/l)	176 ± 24	228 ± 63	209 ± 38	303 ± 97*	151 ± 23	225 ± 116
γ-GTP (IU/l)	0.76 ± 0.19	0.68 ± 0.08	0.64 ± 0.15	0.98 ± 0.22	0.78 ± 0.16	3.28 ± 5.33
Total bilirubin (mg/dl)	0.068 ± 0.011	0.062 ± 0.008	0.058 ± 0.011	0.058 ± 0.008	0.104 ± 0.021	0.340 ± 0.649
Glucose (mg/dl)	158 ± 10	154 ± 19	153 ± 7	144 ± 10	155 ± 11	150 ± 22
Total cholesterol (mg/dl)	65.2 ± 6.5	58.4 ± 10.5	62.4 ± 11.5	49.2 ± 4.8*	72.4 ± 14.6	66.4 ± 14.8
Triglyceride (mg/dl)	29.2 ± 14.6	39.8 ± 17.6	45.6 ± 10.5	21.6 ± 7.4	26.0 ± 21.1	22.8 ± 15.2
BUN (mg/dl)	22.2 ± 2.5	23.2 ± 2.9	21.6 ± 2.3	31.4 ± 3.4**	15.9 ± 2.0	15.5 ± 3.3

Values are given as the mean ± S.D.

*: Significantly different from the control, $p \leq 0.05$ **: Significantly different from the control, $p \leq 0.01$

Repeated dose and reproductive/developmental toxicity of PFOdA

β -globulin fraction and triglyceride, and an increase in the absolute albumin level at 1,000 mg/kg/day in the male recovery group.

In the female main group, no significant change was found in total protein, but in the protein fraction, the α_1 -globulin ratio was significantly lower at 200 and 1,000 mg/kg/day, and the γ -globulin ratio was significantly higher at 1,000 mg/kg/day (Table 2). There were also significant increases in ALP and BUN, and a significant decrease in total cholesterol at 1,000 mg/kg/day in the female main group. In the female recovery group, total protein and α_1 - and β -globulin fractions were significantly lower and the albumin fraction was significantly higher at 1,000 mg/kg/day than in the control.

Organ weight

In males, the absolute and relative liver weight was significantly higher at 200 mg/kg/day and above at the end of the administration period (Table 3). The absolute weight of the heart, spleen and thymus was decreased significantly in males given 1,000 mg/kg/day, but the relative weights of these organs was not changed significantly. In this 1,000 mg/kg/day group, the relative weights of the brain, kidney and testis were significantly increased without significant changes in the absolute weights. At the end of the recovery period, increased liver weight remained significant at 1,000 mg/kg/day. There was also a significant decrease in the absolute heart weight and increase in the relative brain and kidney weight in males given 1,000 mg/kg/day in the recovery group.

In the female main group, there were significant increases in the absolute liver weight at 1,000 mg/kg/day and in the relative liver weight at 200 mg/kg/day and above (Table 3). In the 1,000 mg/kg/day group, the absolute heart weight was decreased and the relative brain weight was increased significantly. In the female recovery group, significant increases in the absolute and relative liver weight and in the relative kidney weight, and a decrease in the absolute heart weight were found at 1,000 mg/kg/day.

Histopathological findings

Histopathological findings of scheduled-sacrifice animals in each group are shown in Table 4. Centrilobular hypertrophy of hepatocytes was observed in males given 200 mg/kg/day and above and centrilobular degeneration/necrosis of hepatocytes in males given 1,000 mg/kg/day at the end of the administration period. For these hepatic changes, the increase in the incidence was statistically significant. In the male main group, there was also focal necrosis at 200 mg/kg/day and above and hemosiderin

deposit (mainly in Kupffer cells) at 1,000 mg/kg/day in the liver, although the incidence was not significantly different from that in the control group. Further, centrilobular fatty change was observed in two males at 200 mg/kg/day, but there was no dose-dependency in the incidence. In the pancreas, the incidence of decreased zymogen granules showed an increasing tendency (not significant) in males given 1,000 mg/kg/day. In the thymus, cortex atrophy was observed in one male in the main group. Centrilobular hypertrophy of hepatocytes, focal necrosis and hemosiderin deposit in the liver and decreased zymogen granules in the pancreas remained after the recovery period in males given 1,000 mg/kg/day. The incidence of centrilobular hepatocyte hypertrophy in the liver and decreased zymogen granules in the pancreas was significantly higher than in the control. A significant increase in the incidence of microgranuloma was also found in the liver in the male recovery group at 1,000 mg/kg/day.

In the female main group, similar histopathological changes were observed in the liver, pancreas and thymus at 1,000 mg/kg/day. The incidence of centrilobular hepatocyte hypertrophy, focal necrosis and microgranuloma in the liver and decreased pancreatic zymogen granules was significantly higher than in the control. In the main group, hemosiderin deposit was observed in the spleen in all females in all dose groups, but the grade was significantly increased at 1,000 mg/kg/day. In addition, periportal fatty change was observed in the control, 40 mg/kg/day and 1,000 mg/kg/day groups, but the incidence did not increase dose-dependently. In the female recovery group, the incidence of centrilobular hypertrophy of hepatocytes and hemosiderin deposit in the liver was significantly higher in the 1,000 mg/kg bw/group.

Reproductive and developmental findings

In the main group, persistent diestrus was found in one female each in the control and 1,000 mg/kg/day group; however, there were no significant deviations in the mean estrous cycle and in the incidence of females with a normal estrous cycle between the control and PFOdA groups either in the main group or in the recovery group (data not shown).

Reproductive performance and developmental findings are summarized in Table 5. During the cohabitation period, copulation was not observed in two males given 1,000 mg/kg/day. In the 1,000 mg/kg/day group, one female with successful copulation was not impregnated, and one pregnant female did not deliver live pups (all pups still-born). There were, however, no significant differences in the copulation, fertility or gestation index, and the pre-coital interval or gestation length between the control and

Table 3. Organ weights of male and female rats given PFOdA

Dose (mg/kg/day)	Main Group				Recovery Group		
	0 (control)	40	200	1000	0 (control)	1000	
MALES							
Number of animals examined	5	5	5	5	5	5	
Brain	(g) (%) ^a	2.15 ± 0.08 0.470 ± 0.024	2.17 ± 0.09 0.478 ± 0.031	2.18 ± 0.11 0.466 ± 0.050	2.14 ± 0.06 0.586 ± 0.038**	2.16 ± 0.11 0.436 ± 0.030	2.16 ± 0.10 0.528 ± 0.026**
Thymus	(mg) (10 ⁻³ %) ^a	297 ± 85 64.5 ± 15.1	271 ± 84 59.6 ± 17.6	335 ± 53 71.6 ± 11.8	178 ± 51* 48.4 ± 10.0	253 ± 33 50.8 ± 6.8	274 ± 94 67.2 ± 23.3
Heart	(g) (%) ^a	1.376 ± 0.084 0.300 ± 0.019	1.398 ± 0.162 0.306 ± 0.021	1.408 ± 0.187 0.298 ± 0.016	1.056 ± 0.100** 0.288 ± 0.018	1.460 ± 0.070 0.294 ± 0.017	1.164 ± 0.139** 0.284 ± 0.030
Liver	(g) (%) ^a	10.9 ± 1.8 2.36 ± 0.28	11.3 ± 1.6 2.48 ± 0.25	15.8 ± 1.8** 3.35 ± 0.14**	18.2 ± 1.2** 5.00 ± 0.13**	11.9 ± 0.3 2.40 ± 0.06	18.3 ± 2.1** 4.46 ± 0.42**
Spleen	(g) (%) ^a	0.738 ± 0.091 0.160 ± 0.020	0.704 ± 0.059 0.156 ± 0.005	0.656 ± 0.087 0.140 ± 0.012	0.580 ± 0.103* 0.160 ± 0.022	0.698 ± 0.055 0.140 ± 0.010	0.682 ± 0.094 0.168 ± 0.027
Kidney ^b	(g) (%) ^a	2.96 ± 0.15 0.648 ± 0.047	2.90 ± 0.22 0.636 ± 0.044	3.08 ± 0.28 0.660 ± 0.076	2.94 ± 0.26 0.806 ± 0.043**	2.93 ± 0.10 0.590 ± 0.019	2.94 ± 0.19 0.718 ± 0.030**
Testis ^{b, c}	(g) (%) ^a	3.28 ± 0.38 0.697 ± 0.124	3.38 ± 0.470 0.702 ± 0.097	3.320 ± 0.227 0.697 ± 0.071	3.421 ± 0.251 0.906 ± 0.066**	3.468 ± 0.190 0.698 ± 0.041	3.270 ± 0.362 0.802 ± 0.096
FEMALES							
Number of animals examined	5	5	5	5	5	5	
Brain	(g) (%) ^a	2.05 ± 0.06 0.652 ± 0.019	2.08 ± 0.11 0.638 ± 0.039	2.09 ± 0.06 0.680 ± 0.061	2.01 ± 0.07 0.738 ± 0.066*	2.04 ± 0.06 0.640 ± 0.034	2.04 ± 0.11 0.788 ± 0.106
Thymus	(mg) (10 ⁻³ %) ^a	268 ± 29 85.1 ± 6.3	322 ± 31* 98.9 ± 14.4	305 ± 27 99.3 ± 11.1	245 ± 34 90.6 ± 17.1	274 ± 24 86.2 ± 11.5	250 ± 86 94.5 ± 27.4
Heart	(g) (%) ^a	1.076 ± 0.048 0.342 ± 0.016	1.104 ± 0.065 0.340 ± 0.028	1.048 ± 0.094 0.340 ± 0.024	0.844 ± 0.056** 0.310 ± 0.016	1.056 ± 0.054 0.330 ± 0.012	0.890 ± 0.071** 0.344 ± 0.040
Liver	(g) (%) ^a	10.2 ± 0.5 3.23 ± 0.16	10.6 ± 0.8 3.23 ± 0.11	11.7 ± 1.0 3.80 ± 0.10**	13.2 ± 1.6** 4.82 ± 0.49**	7.8 ± 0.2 2.4 ± 0.1	10.3 ± 1.2** 3.96 ± 0.53**
Spleen	(g) (%) ^a	0.710 ± 0.056 0.224 ± 0.015	0.766 ± 0.161 0.232 ± 0.046	0.666 ± 0.098 0.218 ± 0.024	0.570 ± 0.045 0.212 ± 0.015	0.556 ± 0.098 0.174 ± 0.030	0.494 ± 0.070 0.186 ± 0.018
Kidney ^b	(g) (%) ^a	2.05 ± 0.20 0.650 ± 0.062	2.04 ± 0.25 0.624 ± 0.061	2.01 ± 0.28 0.648 ± 0.054	1.97 ± 0.10 0.724 ± 0.049	2.00 ± 0.05 0.628 ± 0.030	1.94 ± 0.10 0.752 ± 0.120**
Ovary ^b	(mg) (10 ⁻³ %) ^a	113.8 ± 8.0 35.8 ± 1.5	112.4 ± 9.4 34.3 ± 2.2	102.0 ± 20.4 32.8 ± 4.4	105.2 ± 7.9 38.7 ± 4.7	106.2 ± 12.5 33.3 ± 4.5	81.0 ± 21.7 30.5 ± 5.0

Values are given as the mean ± S.D.

^a: ratio of organ weight to body weight (relative organ weight). ^b: values are represented as the total weights of the organs on both sides. ^c: organ weight was measured for all animals (number of examined animals: 7 at 0 and 1,000 mg/kg/day and 12 at 40 and 200 mg/kg/day in the main group and 5 at 0 and 1000 mg/kg/day in the recovery group)

*: Significantly different from the control, $p \leq 0.05$. **: Significantly different from the control, $p \leq 0.01$

Repeated dose and reproductive/developmental toxicity of PFOdA

Table 4. Histopathological findings in male and female rats given PFOdA

	Grade	Main Group				Recovery Group	
		0 ^a	40 ^a	200 ^a	1000 ^a	0 ^a	1000 ^a
MALES							
Number of animals examined		7	12	12	7	5	5
Liver							
Centrilobular hypertrophy of hepatocytes	+	0	0	12]**	0]**	0	4]**
	++	0	0	0	7	0	1
Centrilobular degeneration/necrosis of hepatocytes	+	0	0	0	4]**	0	0
	++	0	0	0	2]**	0	0
Focal necrosis	+	0	0	1	2	0	2
Microgranuloma	+	5	9	7	6	2	2]*
	++	0	0	0	0	0	3]*
Hemosiderin deposit	+	0	0	0	4	0	2
Centrilobular fatty change	+	0	0	2	0	0	0
Pancreas							
Decrease in zymogen granule	+	1	0	0	4	0	4]*
	++	0	0	0	0	0	1]*
Spleen							
Hemosiderin deposit	+	5	8	8	2	5	5
	++	2	4	4	5	0	0
Thymus							
Atrophy of cortex	+	0	0	0	1	0	0
FEMALES							
Number of animals examined		12	12	12	9 ^b	5	5
Liver							
Centrilobular hypertrophy of hepatocytes	+	0	0	0	8]**	0	4 *
	++	0	0	0	1]**	0	0
Focal necrosis	+	0	0	0	4*	0	0
Microgranuloma	+	4	4	5	2]**	1	3
	++	0	0	0	7]**	0	1
Hemosiderin deposit	+	0	0	0	1	0	5 **
Periportal fatty change	+	3	1	0	2	0	0
	++	0	0	0	0	0	1
Pancreas							
Decrease in zymogen granule	+	0	0	0	8]**	0	1
	++	0	0	0	1]**	0	2
Spleen							
Hemosiderin deposit	+	11	12	10	3]*	0	0
	++	1	0	2	6]*	5	5
Thymus							
Atrophy of cortex	+	0	0	0	1	0	1

Values are the number of animals with findings.

Grade: +: slight change, ++: moderate change.

*: Significantly different from the control at $p \leq 0.05$.

** : Significantly different from the control at $p \leq 0.01$.

^a: Dose (mg/kg/day).

^b: Among 12 females in the main group, three females each were euthanized on day 18 of gestation because of a moribund condition, on day 26 of gestation because of non-pregnancy and on day 1 of lactation because of abnormal delivery (stillbirth).

PFOdA-treated groups.

The number of corpora lutea and implantation sites was significantly lower at 1,000 mg/kg/day than in the control. No significant changes were found in the implan-

tation index. The total number of pups born and the number of live pups on PNDs 0 and 4 were significantly lower at 1,000 mg/kg/day. There was no significant difference in the delivery, live birth and viability indices

Table 5. Reproductive performance and developmental findings in rats given PFOdA

Dose (mg/kg/day)	0 (control)	40	200	1000
Number of pairs	12	12	12	12
Copulation index (%) ^a Male	100	100	100	83.3
Female	100	100	100	100
Precoital interval (day) ^b	2.8 ± 0.9	2.5 ± 1.2	2.8 ± 0.9	1.9 ± 1.1
Fertility index (%) ^c	100	100	100	91.7
Gestation index (%) ^d	100	100	100	90
Gestation length (days) ^b	22.4 ± 0.5	22.2 ± 0.4	22.2 ± 0.4	22.1 ± 0.3
Number of pregnant females	12	12	12	10
Number of corpora lutea ^b	16.6 ± 1.4	17.2 ± 1.8	15.3 ± 2.0	14.0 ± 2.4**
Number of implantation ^b	16.4 ± 1.3	16.6 ± 1.7	15.0 ± 2.0	14.0 ± 2.4*
Implantation index (%) ^{b, e}	99.1 ± 2.2	96.8 ± 5.5	98.4 ± 2.8	100.0 ± 0.0
Number of litters	12	12	12	9
Total number of pups born ^b	15.5 ± 1.2	15.3 ± 1.6	14.3 ± 2.1	11.2 ± 3.6**
Delivery index (%) ^{b, f}	94.6 ± 5.8	92.7 ± 8.2	95.4 ± 4.5	80.4 ± 22.0
Sex ratio of pups born ^{b, g}	0.524 ± 0.135	0.450 ± 0.092	0.438 ± 0.136	0.410 ± 0.105
Number of live pups on PND 0 ^b	15.5 ± 1.2	15.3 ± 1.6	14.3 ± 2.1	10.0 ± 5.0**
Live birth index (%) ^{b, h}	100.0 ± 0.0	100.0 ± 0.0	100.0 ± 0.0	84.2 ± 32.6
Number of live pups on PND 4 ^b	15.4 ± 1.2	14.8 ± 1.5	13.8 ± 2.3	10.6 ± 3.5**
Viability index (%) ^{b, i}	99.4 ± 1.9	96.9 ± 5.0	96.1 ± 9.2	94.8 ± 8.7
Male pups				
Body weight (g) on PND 0 ^b	7.03 ± 0.70	6.63 ± 0.57	6.66 ± 0.51	5.39 ± 0.87**
on PND 1 ^b	7.72 ± 0.80	7.22 ± 0.65	7.32 ± 0.61	5.60 ± 0.86**
on PND 4 ^b	11.08 ± 1.24	10.53 ± 0.99	10.73 ± 1.02	7.96 ± 1.19**
Body weight gain (g) on PNDs 0-4 ^b	4.05 ± 0.62	3.90 ± 0.58	4.08 ± 0.88	2.57 ± 0.68**
Female pups				
Body weight (g) on PND 0 ^b	6.63 ± 0.76	6.18 ± 0.48	6.38 ± 0.51	5.11 ± 0.86**
on PND 1 ^b	7.26 ± 0.92	6.78 ± 0.62	6.94 ± 0.58	5.34 ± 0.84**
on PND 4 ^b	10.50 ± 1.31	9.88 ± 1.06	10.12 ± 0.86	7.76 ± 1.17**
Body weight gain (g) on PNDs 0-4 ^b	3.88 ± 0.67	3.70 ± 0.71	3.74 ± 0.63	2.64 ± 0.75**

^a Copulation index (%) = (no. of animals with successful copulation/no. of animals mated) × 100^b Values are given as the mean ± S.D.^c Fertility index (%) = (no. of pregnant females/no. of females with successful copulation) × 100^d Gestation index (%) = (no. of females that delivered live pups/no. of pregnant females) × 100^e Implantation index = (no. of implantation sites/no. of corpora lutea) × 100^f Delivery index = (no. of pups born/no. of implantation sites) × 100^g Sex ratio of pups born = (no. of male pups born/no. of female pups born)^h Live birth index = (no. of live pups on PND 0/no. of pups born) × 100ⁱ Viability index = (no. of live pups on PND 4/no. of live pups on PND 0) × 100*: Significantly different from the control at $p \leq 0.05$ **: Significantly different from the control at $p \leq 0.01$

Repeated dose and reproductive/developmental toxicity of PFOdA

between the control and PFOdA-treated groups, but these indices indicated a decreasing tendency at 1,000 mg/kg/day. In the 1,000 mg/kg/day group, the body weight of male and female pups was significantly lower than in the control on PNDs 0, 1 and 4. Body weight gain for the 4 days after birth was significantly decreased in males and females given 1,000 mg/kg/day. Gross external and internal observation did not reveal any treatment-related alterations either in pups that survived until PND 4 or pups found dead during the postnatal period (data not shown).

DISCUSSION

PFAAs are known to affect the liver, causing hypertrophy and in some cases necrosis, in rodents (Chengelis *et al.*, 2009; Goldenthal, 1978; Griffith and Long, 1980; Kawashima *et al.*, 1995; Kennedy, 1987; Lieder *et al.*, 2009b; Mertens *et al.*, 2010; van Otterdijk, 2007a, 2007b; Zhang *et al.*, 2008). Hepatocyte hypertrophy was observed at as low as 0.064–0.23 mg/kg/day in a 2-year dietary study of PFOS (Thomford, 2002) and 0.64 mg/kg/day in a 13-week dietary study of PFOA (Perkins *et al.*, 2004) in rats. Such hepatic effects of PFAAs are considered to be exerted via the peroxisome proliferator-activated receptor alpha (PPAR α), but other mechanisms have also been suggested (Lau *et al.*, 2007). Kudo *et al.* (2006) reported that intraperitoneal administration of PFAAs with six- to nine-carbon length increased the liver weight and hepatic peroxisomal β -oxidation activity in mice, and the potency was in the order of perfluorononanoic acid (PFNA; C9) \approx PFOA (C8) > perfluoroheptanoic acid (PFHpA; C7) > perfluorohexanoic acid (PFHxA; C6). In the other study, PFOA (C8) and perfluorodecanoic acid (PFDeA; C10) considerably increased the liver weight, and hepatic peroxisomal palmitoyl- and lauroyl-CoA oxidase activities, but the responses to perfluorobutanoic acid (PFBA; C4) were lower and perfluoroacetic acid (C2) was inactive in male mice fed a diet containing PFAAs (Permadi *et al.*, 1993). These data suggest that the toxic potency of PFAAs increased with lengthening of the carbon chain, at least up to C9. Such carbon chain length dependency is considered to be associated with the difference in the elimination rate of PFAAs: the elimination half-life was reported to be 6.38 hr for PFBA (C4), 2.4 hr for PFHpA (C7), 135–185 hr for PFOA (C8), 710 hr for PFNA (C9) and 958 hr for PFDeA (C10) in male rats administered intravenously with PFAAs (Chang *et al.*, 2008; Kemper 2003; Kudo *et al.*, 2002; Ohmori *et al.*, 2003).

The present study demonstrated that the major target of the toxicity of PFOdA (C18) was the liver as with the other PFAAs. Centrilobular hepatocyte hypertro-

phy and necrosis were observed in males given 200 and 1,000 mg/kg/day and in females given 1,000 mg/kg/day. Increased incidence of microgranuloma was considered to be a reparative response to the hepatic injury. These histopathological changes were accompanied with increased liver weight and leaking out of hepatic enzymes. Such hepatic changes were not observed in the 40 mg/kg/day group, indicating that the toxic potency of PFOdA was unexpectedly low. Differences in the toxic potency of PFOdA and the other PFAAs with shorter carbon chain might come from differences in the elimination rate from the body, as suggested for the other PFAAs. However, since hepatic effects of PFOdA as well as other toxic effects observed at the end of the administration period were detected even after the 14-day recovery period in the present study, the elimination rate of PFOdA was considered to be slow as with PFOA, PFNA and PFDeA (Kemper, 2003; Kudo *et al.*, 2002; Ohmori *et al.*, 2003). Intestinal absorption or distribution in the body might differ between PFOdA and other PFAAs. Other possible factors included toxicodynamic determinants, such as PPAR α agonistic activity. In the present study, hepatocyte hypertrophy was not accompanied with eosinophilic granular cytoplasm, which is a characteristic change observed in rodents administered with peroxisome proliferators. In addition, no clear effects on lipid metabolism were found in blood biochemical examination, except for decreased serum cholesterol observed in females given 1,000 mg/kg/day. Therefore, the peroxisome proliferative activity of PFOdA was considered weak, if any, and there is the possibility that a different mechanism from peroxisome proliferation is involved in the hepatotoxicity of PFOdA. Further study is needed to clarify the cause of the difference in the toxic potency of PFOdA and the other PFAAs.

In the present study, one female given 1,000 mg/kg/day was found moribund on day 18 of gestation. General appearance and behavior suggest that the moribund state might be associated with anemia caused by bleeding from vagina. Although hematological examination was not performed for this animal, the effect of PFOdA on blood coagulation (discussed below) might be involved in the vaginal bleeding during late pregnancy. In other animals, no clinical signs of toxicity were found. In the female main group, forelimb grip strength was reduced on day 4 of lactation at 1,000 mg/kg/day. No such effect was detected at the end of the 42-day administration in males and in the female recovery group. This result might be due to the higher maternal body burden of PFOdA during pregnancy in comparison to males and non-pregnant females in the same dose group, because the dose level for pregnant females was determined based on the weight

of the pregnant body containing fetuses. Further, altered physical condition during the gestation and lactation periods could make their toxic susceptibility higher. However, considering that no other dose-related changes were found in detailed clinical and functional observations, the toxicological significance of this forelimb grip weakness is unclear. Effects on grip strength were examined in 90-day repeated oral dose toxicity studies of PFBA, perfluorohexanoic acid (PFHxA) and perfluorobutane sulfonic acid (PFBS) in rats, but no dose-related changes were reported (Chengelis *et al.*, 2009; Lieder *et al.*, 2009a; van Otterdijk, 2007b).

Body weight gain of male and female rats was markedly inhibited at 1,000 mg/kg/day in the present study. Although decreases in body weight coincided with the reduction of food consumption during PFOdA administration, they were hardly recovered during the 14-day recovery period when food consumption was not different between the control and 1,000 mg/kg/day group. The effects on body weight are typically observed in rodents given PFAAs at relatively high doses (ATSDR, 2009). Interestingly, these effects are not associated with reduced food intake in many cases. For example, 7-day or 10-day dietary administration of PFOA at 0.02% caused more than 10% reduction of body weight, compared with the control (Xie *et al.*, 2003; Yang *et al.*, 2000). In these studies of PFOA, food intake was not reduced significantly. Yang *et al.* (2002) reported that body weight gain was not inhibited in PPAR α -null mice given PFOA with the same dose regimen, suggesting that PPAR α activation is involved in the body weight effects of PFAAs. In the present study, however, no clear effects indicating the alteration of lipid metabolism were found as mentioned above. The other mechanisms may contribute to the effects of PFOdA on body weights.

PFOdA affected various hematological parameters at 200 mg/kg/day and above. Anemic effects observed in males (i.e. reduced red blood cell count, hemoglobin level and hematocrit) were previously reported in repeated oral dose studies of PFBA, PFHxA, PFOA, PFBS and PFOS in rats (Chengelis *et al.*, 2009; Goldenthal *et al.*, 1978; Lieder *et al.*, 2009a; Sibinski, 1987; van Otterdijk, 2007b); however, the mechanism has yet to be revealed. In the present study, increased serum total bilirubin and hepatic hemosiderin deposition indicated a hemolytic effect of PFOdA. A decrease in reticulocyte ratio also suggests a decline in hematopoietic function, but histopathological examination of bone marrow did not reveal any abnormalities. At the end of the recovery period, the reticulocyte ratio was considerably increased, but reduced red blood cells, hemoglobin and hematocrit did not indi-

cate recovery. In females, these anemic changes were not found, but the number of basophils was increased at 1,000 mg/kg/day. Its etiology and toxicological significance is unknown. Blood clotting parameters were also affected in females. Prolongation of APTT suggests the inhibition of an intrinsic and/or common pathway in blood coagulation. Shortening of PT was considered to be toxicologically insignificant, but showed that PFOdA does not inhibit the extrinsic pathway of coagulation. At the end of the recovery period, this effect on APTT was also observed in males. Elevation of basophils and prolongation of APTT were not reported in previous studies of other PFAAs (ATSDR, 2009). In order to gain a better understanding of the etiology of the hematological effects occurring in male and female rats given PFOdA, additional investigations are needed.

In the 1,000 mg/kg/day group, other dose-related changes were found in blood biochemical variables, organ weights and histopathological findings. In males, serum total protein was reduced, and this change seemed to result primarily from a decrease in the globulin α_1 fraction, which was also found in females given 200 and 1,000 mg/kg/day. Since most serum proteins, with the exception of γ -globulin, are synthesized, and also degraded in the liver (Ove *et al.*, 1972), observed effects on serum protein may be attributable to hepatic effects of PFOdA, although other etiologies could be responsible. An elevated serum level of BUN, observed in both sexes, increases the likelihood that the hepatic protein catabolism was increased because urinalysis parameters and the gross and microscopic appearance of the kidneys were not affected by PFOdA treatment. In the pancreas, zymogen granules were decreased in both sexes. This change might result from increased pancreatic secretion of digestive juice. Lipids are known to stimulate pancreatic secretion, and long chain fatty acids stimulate this more intensively than medium chain fatty acids (Ioannidis *et al.*, 2008), which might explain why such effects on the pancreas were not reported for the other PFAAs (ATSDR, 2009).

As for the reproductive/developmental effects, all pups were stillborn in one pregnant female given 1,000 mg/kg/day. Although the incidence was low, the possibility that this change was treatment-related could not be ruled out because of the very low incidence of such effect (all pups stillborn) in the laboratory's historical control data (approximately 0.5~1.0%). Another pregnant female given 1,000 mg/kg/day was found moribund during late pregnancy as described above, suggesting that PFOdA might have a certain effect on the maintenance of pregnancy. In the 1,000 mg/kg/day group, the number of corpora lutea was slightly decreased. Such effects on the